naltrexone has been researched along with Cancer of Pancreas in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berkson, AJ; Berkson, BM; Rubin, DM | 2 |
| McLaughlin, PJ; Zagon, IS | 1 |
| Hankins, J; McLaughlin, PJ; Verderame, MF; Zagon, IS | 1 |
| Levin, RJ; McLaughlin, PJ; Ohlsson-Wilhelm, BM; Roesener, CD; Verderame, MF; Zagon, IS | 1 |
5 other study(ies) available for naltrexone and Cancer of Pancreas
| Article | Year |
|---|---|
Revisiting the ALA/N (alpha-lipoic acid/low-dose naltrexone) protocol for people with metastatic and nonmetastatic pancreatic cancer: a report of 3 new cases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Fatal Outcome; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Naltrexone; Pancreatic Neoplasms; Thioctic Acid | 2009 |
Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Adhesion; Cell Division; Colonic Neoplasms; Colony-Forming Units Assay; Enkephalin, Methionine; Head and Neck Neoplasms; Humans; Naloxone; Naltrexone; Narcotic Antagonists; Pancreatic Neoplasms; Receptors, Opioid; Transplantation, Heterologous; Tumor Cells, Cultured | 2004 |
The long-term survival of a patient with pancreatic cancer with metastases to the liver after treatment with the intravenous alpha-lipoic acid/low-dose naltrexone protocol.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Biopsy, Needle; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Immunohistochemistry; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Naltrexone; Neoplasm Staging; Palliative Care; Pancreatic Neoplasms; Thioctic Acid; Time Factors; Treatment Outcome | 2006 |
Overexpression of the opioid growth factor receptor potentiates growth inhibition in human pancreatic cancer cells.
Topics: Cell Count; Cell Line, Tumor; Cell Proliferation; DNA; Genetic Therapy; Humans; Naltrexone; Narcotic Antagonists; Pancreatic Neoplasms; Receptors, Opioid; Transfection; Up-Regulation | 2007 |
Opioid growth factor regulates the cell cycle of human neoplasias.
Topics: Adenocarcinoma; Carcinoma, Squamous Cell; Cell Cycle; Cell Division; Colonic Neoplasms; DNA Replication; Enkephalin, Methionine; Head and Neck Neoplasms; Humans; Naltrexone; Narcotic Antagonists; Neoplasm Proteins; Neoplasms; Pancreatic Neoplasms; Receptors, Opioid; Resting Phase, Cell Cycle; Tumor Cells, Cultured; Tumor Stem Cell Assay | 2000 |